Study Reveals Long-Term Effects On Child IQ Of Epilepsy Drug Valproate During Pregnancy
Main Category: EpilepsyAlso Included In: Pediatrics / Children's Health; Pregnancy / Obstetrics; Neurology / Neuroscience
Article Date: 23 Jan 2013 - 5:00 PST
Study Reveals Long-Term Effects On Child IQ Of Epilepsy Drug Valproate During Pregnancy
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
4.5 (2 votes) |
| Article opinions: | 1 posts |
Research published today in The Lancet Neurology shows that taking the antiepileptic drug valproate during pregnancy affects the IQ of children up to the age of six.
Research published in 2009 showed that maternal valproate use during pregnancy affected children's IQ at three years old, leading the US Food and Drug Administration (FDA) to issue a warning that foetal valproate exposure is associated with impaired cognitive outcomes. The new research reports on the same group of children - whose mothers used one of four common antiepileptic drugs, including valproate, during pregnancy - at six years old. Due to the children's advanced age, the researchers were able to examine a wider range of cognitive indicators, such as verbal ability and memory, than in the earlier study. They also investigated the effect that folic acid supplementation in the mothers had on the IQ and reasoning ability of their children.
Between October 1999 and February 2004, the researchers, led by Professor Kimford Meador at Emory University in the US, recruited 305 pregnant women in the UK and the US, who were using a single drug to treat epilepsy (valproate, carbamazepine, lamotrigine, or phenytoin). At age six, children whose mothers had used valproate during pregnancy had reduced IQ (by 7-10 points), compared with children from mothers who had used the other antiepileptic drugs included in the study. Valproate exposure was also associated with worse verbal and memory abilities.
The effects of valproate on IQ and other cognitive abilities were dependent on the dose, with the children of women who took higher doses of the drug having lower IQs, verbal, non-verbal, memory, and executive abilities. However, the findings also suggest that IQ may improve with age for infants exposed to valproate or any of the other drugs studied, and that folic acid supplementation in mothers may improve IQ scores, the first time that this has been shown in a study of pregnant women with epilepsy. For some people, valproate is the only drug that can control their epilepsy, so the findings on dose-dependency and the potential positive effects of folic acid supplementation on IQ may prove particularly important.
According to Professor Meador, "These results build on our earlier work to show that valproate usage during pregnancy has a significant negative effect on children's IQ, which lasts beyond their earliest years. IQ at age six is strongly predictive of adult IQ and school performance, so our research suggests that valproate use during pregnancy is likely to have long-term negative effects on a child's IQ and other cognitive abilities. For many antiepileptic drugs, there is simply no research available on their effects on women and their children during pregnancy, and given that many women do not have the option of stopping medication during pregnancy, more research in this area is urgently needed."*
* Quote direct from author and cannot be found in text of Article.
Visit our epilepsy section for the latest news on this subject.
The Lancet Neurology, Early Online Publication, 23 January 2013 doi:10.1016/S1474-4422(12)70323-X
MLA
18 May. 2013. <http://www.medicalnewstoday.com/releases/255279.php>
APA
http://www.medicalnewstoday.com/releases/255279.php.
Please note: If no author information is provided, the source is cited instead.
Visitor Opinions (latest shown first)
Valproate Reduces Maternal DHEA necessary for Fetal Brain Growth and Development
posted by James on 23 Jan 2013 at 6:31 amI suggest the basis of your, et al., findings result from adverse effects of valproate on maternal DHEA and testosterone which also affect fetal growth and development.
It is my hypothesis that evolution selected increased testosterone during evolution of primates and humans. ("Androgens in Human Evolution," Rivista di Biologia / Biology Forum 2001; 94: 345-362) This occurred because testosterone increases androgen receptor production which increases absorption and use of dehydroepiandrosterone (DHEA). (Mammals evolved because of selection for DHEA: "Hormones in Mammalian Evolution," Rivista di Biologia / Biology Forum 2001; 94: 177-184.) The effect of increased testosterone in primates / humans occurred because of increased maternal testosterone. This increased androgen receptors within fetal brains which increased growth and development, hence, bigger brains. This reached a maximum in humans with the selection by evolution of females of very high testosterone. (Human male and female testosterone is higher than chimpanzee male and females; human and chimpanzee estrogen are approximately equivalent.)
The extra use of DHEA by our bigger brains changes the use of our DHEA by our bodies. Bigger brains produced the changes in our bodies that differentiate us from the other primates because of competition between the brain and other tissues for DHEA.
It is known that "Valproic acid, an enzyme inhibitor, has been associated with the occurrence of reproductive endocrine disorders characterized by high serum T, free androgen index, androstenedione, dehydroepiandrosterone sulfate concentrations, and with polycystic changes in ovaries and menstrual disorders." (Epilepsia. 2011 Feb;52(2):199-211)
I also suggest that high levels of dehydroepiandrosterone sulfate (DHEAS) indicate that DHEA, the active molecule, is not being produced. Since maternal DHEA is used by both the mother and fetus, valproate treatment reduces available DHEA for the growth and development of the fetal brain. This may account for the findings of Meador, et al.
Add Your Opinion On This Article
'Study Reveals Long-Term Effects On Child IQ Of Epilepsy Drug Valproate During Pregnancy'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



